Squamous cell neoplasm

This trial studies a new drug called SLC-3010, given alone or with chemotherapy (gemcitabine), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to find safe doses and see if the drug can shrink tumors. The study is in two par…

This early-stage study tested a new drug called Debio 0123 in 66 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to find the safest dose and to check for side effects and any signs that the drug could shrink tumors. The st…

This study tested a drug called bemarituzumab in 260 adults with solid tumors that have high levels of a protein called FGFR2b. The main goals were to see if the drug is safe and if it can shrink tumors. Participants had already tried other treatments without success.

This early-stage study tested a new drug called CLN-617, alone or with the immunotherapy Keytruda, in 23 adults with advanced solid tumors that had not responded to standard treatments. The goal was to check safety and find the right dose. However, the trial was terminated, so fu…

This study tested a new drug called PRS-344/S095012 in people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the right dose. The trial was stopped early, and only 46 people took part.

This trial tested an experimental drug called ASP1570 in adults with advanced solid tumors that had spread or could not be removed by surgery. The drug aims to help the body's immune T-cells attack tumors that have become resistant. The study was in two parts: first to find a saf…

This early-phase trial tested a combination of two oral drugs, mirdametinib and brimarafenib, in 23 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to check safety, find the best dose, and see if the combo could shrink tumors. Th…

This early-stage study tested a new drug called VVD-130850, which blocks a protein (STAT3) that helps cancers grow. The trial aimed to find a safe dose and see if the drug works, both alone and with another immunotherapy, in people with advanced solid tumors or blood cancers. The…

This study tested whether injecting vidutolimod directly into tumors plus giving cemiplimab through a vein could shrink cancers that have spread. The trial included 77 people with several types of advanced cancer. Unfortunately, the study was stopped early, so we have less inform…

This early-phase trial tested a new oral drug called BBI-355, alone or with other targeted therapies, in people with advanced solid tumors that had extra DNA (oncogene amplifications). The study aimed to find the safest dose and check for side effects. It was terminated early, so…

This early-stage study tested a new drug called PF-07265807 in people with advanced or metastatic solid tumors that had spread. The main goals were to find a safe dose and check for side effects. The trial was terminated early, so results are limited.

This study tested a new drug (INCB099280) combined with a standard cancer drug (axitinib) in adults with advanced solid tumors that had stopped responding to other treatments. The main goals were to check safety and see if the combination could shrink tumors. The trial was termin…

This phase 2 trial tested whether the immunotherapy drug atezolizumab could shrink head and neck skin cancers that had spread to lymph nodes before surgery. Only 1 person enrolled before the study was terminated early. The goal was to see if the drug could eliminate all cancer ce…

This early-stage trial tested a new drug called 2X-121, alone and combined with another drug called dovitinib, in 14 people with advanced solid tumors. The goal was to find the safest dose and check for side effects. The study was terminated early, so results are limited and no c…

This early-phase study tested a new drug called eciskafusp alfa, alone or with another immunotherapy (atezolizumab), in 189 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the right dose. The study…

This study tested a combination of an immunotherapy drug (nivolumab) and low-dose chemotherapy in children and teenagers whose solid tumors had not responded to standard treatments. The goal was to see if the combination was safe and could help control the cancer. The trial was s…

This phase II trial tested the drug abemaciclib in 7 people with HPV-negative head and neck cancer. Participants took the drug for 10 to 28 days before their planned surgery. The goal was to see if the drug could shrink tumors and to check for side effects. The study was terminat…

This phase II trial tested two drug combinations—ibrutinib plus nivolumab or ibrutinib plus cetuximab—in patients with recurrent or metastatic head and neck squamous cell carcinoma. The goal was to see if these combinations could shrink tumors or slow disease progression. However…

This early-phase trial tested a new immunotherapy called BI 1821736 in 10 adults with advanced solid tumors that had not responded to standard treatments. BI 1821736 is a specially designed virus meant to kill cancer cells and help the immune system fight the cancer. Participants…

This study tested a personalized treatment using immune cells taken from a patient's own tumor, called tumor-infiltrating lymphocytes (TIL). The cells were grown in a lab and given back to the patient to fight their cancer. The trial included people with advanced melanoma, head a…

This early-phase trial tested an oral drug called DT-9081 in 29 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to find a safe dose and check for side effects. The study was terminated early, so full results are not available.

This study tested a new drug, GEN1286, in 23 adults with advanced solid tumors that had spread or could not be removed by surgery. The goal was to check the drug's safety and see if it could shrink tumors. The trial was stopped early, so results are limited.

This early-phase study tested a new drug called PF-08046032, given alone or with another drug (sasanlimab), in adults with advanced lymphomas or solid tumors like lung cancer and melanoma. The trial aimed to check safety and find the right dose, but it was terminated early after …

This early-stage study tested a new drug called NM6603 in 17 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to find the safest dose and check for side effects. The trial was ended early, so results are limited.

This study tested a personalized mRNA vaccine (mRNA-4157) combined with the immunotherapy drug pembrolizumab for people with advanced but removable skin cancer (cutaneous squamous cell carcinoma). The goal was to see if the combination could prevent the cancer from coming back be…

This early-stage trial tested a new drug called AXN-2510 in adults with advanced solid tumors that had stopped responding to other treatments. The drug is a special antibody that targets two cancer pathways at once. However, the study was terminated early after enrolling only 3 p…

This study tested a new drug called PF-08046052/SGN-EGFRd2 in people with advanced solid tumors that could not be removed or had spread. The goal was to find a safe dose and check for side effects. The trial was terminated early, and it included people with colorectal, lung, head…

This study looked at adding two immunotherapy drugs (ipilimumab and nivolumab) to standard radiation for people with advanced HPV-positive throat cancer. The goal was to see if the combination was safe and could shrink tumors better than radiation alone. The trial enrolled 37 par…

This study tested a new drug called serabelisib combined with a diet that lowers insulin levels, with or without another chemotherapy drug, in people with advanced solid tumors that have a specific genetic change (PIK3CA mutation). The goal was to see if the diet could reduce sid…

This early-phase study tested a personalized cell therapy made from a patient's own tumor-fighting immune cells. It aimed to see if the treatment was safe for people with advanced solid tumors that had spread or come back. Only 2 people took part before the study was stopped earl…

This early-phase trial tested a personalized treatment called GT201 for people with advanced solid tumors that had spread or returned. The therapy uses a patient's own immune cells (tumor-infiltrating lymphocytes) that are collected from a tumor, multiplied in a lab, and then inf…

This early-phase trial tested a personalized therapy called GT201, made from a patient's own tumor-fighting immune cells (TILs), for advanced solid tumors. Only 6 people were enrolled before the study was terminated. The treatment involved intensive chemotherapy followed by infus…

This early-phase trial tested OMX-0407, a new drug that blocks certain enzymes, in 68 adults with advanced solid tumors that had stopped responding to other treatments. The study aimed to find a safe dose and check if the drug could shrink tumors. However, the trial was terminate…

This early-stage study tested a new drug called NB004 in 25 adults with advanced solid tumors that had no standard treatment options. The main goal was to check the drug's safety and how the body processes it. The study was terminated early, so results are limited.

This early-stage study tested an experimental oral drug called M1069 in 15 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the right dose. The trial was terminated early, so results are limited and…

This early-phase study tested a new drug called BPT567 in 20 adults with advanced solid tumors that had stopped responding to standard treatments. The drug is designed to help the immune system fight cancer by targeting PD-1 and delivering an immune-boosting protein (IL-18). The …

This study tested whether matching specific targeted drugs to the genetic changes in a person's ALK-positive lung cancer could improve treatment. It included 10 adults with advanced non-small cell lung cancer that had already been treated. The trial was stopped early due to low e…

This early-stage study tested a new drug called PF-08046037, alone or with another drug (sasanlimab), in 8 people with advanced lung, pancreatic, melanoma, or head & neck cancers. The goal was to check safety and how the body handles the drugs. The trial was terminated early, so …

This early-stage trial tested an oral drug called AUR105 in 17 adults with advanced solid tumors or lymphomas that had not responded to prior treatments. The study aimed to find a safe dose and check how the drug moves through the body. However, the trial was terminated, so resul…

This early-phase study tested a new drug called AUR103 Calcium in 27 adults with advanced solid tumors, acute myeloid leukemia, myelodysplastic syndromes, or non-Hodgkin lymphoma who had no other treatment options. The goal was to find the best dose and check safety. The study wa…

This early-phase trial tested a personalized cell therapy called ITIL-306 in people with advanced ovarian, lung, or kidney cancers that had not responded to standard treatments. The therapy uses a patient's own immune cells (TILs) taken from their tumor, modified to better attack…

This early-stage trial tested an oral drug called TNO155, alone or with another drug (nazartinib), in 227 adults with advanced solid tumors like lung cancer, melanoma, and head/neck cancer. The main goal was to check safety and find the right dose. The study was terminated early,…

This study tested a new drug called GEN1047 in people with advanced solid tumors (breast, endometrial, ovarian, or lung cancer) who had no other treatment options. The goal was to check safety, side effects, and how the body processes the drug. The study was terminated early, but…

This early-stage trial tested an investigational drug called TransCon TLR7/8 agonist, alone or with the immunotherapy pembrolizumab, in people with advanced solid tumors that could not be cured by surgery or radiation. The study aimed to find a safe dose and check for side effect…

This early-phase trial tested a new drug called BAT8007 in 93 people with advanced solid tumors that had stopped responding to standard treatments. The drug is designed to target a protein called Nectin-4 on cancer cells and deliver a chemotherapy agent directly to them. The main…

This early-stage study tested a new drug called DR30303 in 13 people with advanced digestive system cancers that had stopped responding to standard treatments. The drug is a lab-made antibody designed to target a protein called CLDN18.2 found on some cancer cells. The main goals …

This early-phase trial tested whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard chemoradiation is safe for people with stage IV head and neck cancer. Only 3 patients were enrolled before the study was stopped. The main goal was to find the highest safe do…

This early-stage study tested a new drug combination (MGN1703 plus ipilimumab) in people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to find the safest dose of MGN1703 when given with ipilimumab. The study was stopped early, bu…

This early-stage study tested a new drug called CPO-100 in 34 adults with advanced solid tumors that had not responded to at least two prior treatments. The goal was to check safety and find the right dose. The study was terminated early, so results are limited.

This early-stage trial tested an experimental drug called xevinapant combined with standard chemotherapy and radiation in people with head and neck cancer who cannot take the usual drug cisplatin. The goal was to find the safest dose of xevinapant. The study was terminated early,…

This early-phase trial tested a new drug called nanrilkefusp alfa, which helps activate immune cells, both alone and combined with the immunotherapy pembrolizumab. It included 115 people with various advanced solid tumors that had stopped responding to standard treatments. The st…

This phase 2 trial tested whether adding radiotherapy to the immunotherapy drug pembrolizumab (Keytruda) helps shrink tumors in people with metastatic head and neck cancer that has spread. The study planned to enroll 115 participants, but was terminated early. Researchers measure…

This early-stage trial tested an experimental immunotherapy called IMU-201 (PD1-Vaxx) in 24 adults with advanced non-small cell lung cancer. The treatment was given alone or combined with another immunotherapy drug (atezolizumab) and sometimes chemotherapy. The goal was to check …

This early-phase study tested a new drug called PF-07921585, given alone or with another drug (sasanlimab), in adults with advanced solid tumors like lung, bladder, kidney, melanoma, head & neck, or colorectal cancer. The goal was to check safety and find the right dose. Only 4 p…

This early-phase trial tested whether adding the immunotherapy drug durvalumab to standard chemotherapy (docetaxel, cisplatin, and 5-FU) is safe for people with advanced head and neck cancer. Only 14 patients were enrolled before the study was stopped. The goal was to find the ri…

This early-phase study tested an experimental drug called DS-9606a in 88 people with advanced solid tumors that have a specific protein (Claudin-6). The main goal was to check safety and find the right dose. The trial was terminated, meaning it stopped before completion, so we ha…

This early-stage study tested a new drug called PF-08046031 in 11 adults with advanced melanoma or other solid tumors that had spread or had no standard treatment options. The main goal was to check the drug's safety and side effects. The trial was terminated early, so its findin…

This early-phase study tested a new drug called GEN2, given with another drug (valganciclovir), in 37 adults with advanced solid tumors that had stopped responding to other treatments. The goal was to find a safe dose and check for side effects. The study was terminated, so resul…

This study tested a new experimental drug, BGB-A3055, alone or with another drug (tislelizumab), in people with advanced or metastatic solid tumors. The goal was to check safety, how the body handles the drug, and any early signs of tumor shrinkage. The study was stopped early, b…

This early-phase study tested a new treatment for adults with advanced solid tumors that had not responded to standard therapies. The treatment combined a cancer-killing virus (onCARlytics) with an immune-boosting drug (blinatumomab), given either into the tumor or through a vein…

This early-stage study tested a new treatment called VAXINIA (CF33-hNIS), a virus designed to attack cancer cells, in 66 adults with advanced solid tumors that had spread. The treatment was given alone or with the immunotherapy drug pembrolizumab, either as a shot into the tumor …

This early-phase trial tested an oral drug called DCC-3084, alone or with other cancer treatments, in 29 people with advanced solid tumors that have MAPK pathway mutations (like certain lung, pancreatic, or skin cancers). The study aimed to find safe doses and see if tumors shrin…

This early-stage study tested a new oral drug, ATX-559, in 17 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to find a safe dose and check for side effects. The study was terminated early, so results are limited.

This early-stage study tested a new drug called PF-07826390, given alone or with another drug (sasanlimab), in people with advanced solid tumors like lung, kidney, and colorectal cancers. The goal was to check safety and find the right dose. Only 10 people took part, and the stud…

This early-phase study tested a new drug called BGB-24714, which is designed to help cancer cells die. It was given alone or with chemotherapy to 157 adults with advanced solid tumors that had spread or could not be removed. The main goal was to find a safe dose and see how well …

This phase II trial tested the drug poziotinib in 93 people with advanced non-small cell lung cancer that has specific changes in the EGFR or HER2 genes. The goal was to see if the drug could shrink tumors or stop them from growing. The study was terminated early, so results are …

This study tested giving the immunotherapy drug nivolumab along with chemotherapy before surgery for people with early-stage non-small cell lung cancer (stages I to IIIA). The goal was to see if this combination could shrink tumors enough to leave less than 10% cancer cells in th…

This study tested a vaginal insert called ABI-2280 in women with cervical precancerous lesions (CIN). The goal was to see if it was safe and could help clear the abnormal cells. The trial was stopped early, so we don't have full results. It involved 44 women aged 25-55 who used t…

This study tested whether adding the drug xevinapant to standard radiation therapy could help prevent head and neck cancer from coming back after surgery. It included 166 people with high-risk cancer who could not take the usual chemotherapy drug cisplatin. The trial was stopped …

This early-phase study tested a new drug, WBC100, in 68 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find the best dose, and see how the drug moves through the body. The trial was terminated, so results…

This early-stage study tested an experimental oral drug (PF-07265028) alone or combined with an immunotherapy injection (sasanlimab) in 21 people with advanced solid tumors, including stomach, lung, and head/neck cancers. The main goals were to find a safe dose and check for side…

This early-stage trial tested a new drug, QEQ278, in 30 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check the drug's safety and find the right dose. The study was stopped early, so results are limited.

This early-stage trial tested a new drug called MRTX0902, alone or with another drug (adagrasib), in 64 people with advanced solid tumors that have certain gene mutations (KRAS-MAPK pathway). The main goals were to check safety and how the drug moves through the body. The trial w…

This study tested an experimental drug called vobramitamab duocarmazine in people with advanced prostate cancer and other solid tumors that stopped responding to standard treatments. The goal was to see if the drug could shrink tumors or slow cancer growth. The trial was terminat…

This early-stage trial tested a new drug called SIM0501, alone or with another drug (olaparib), in 13 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and how the drug moves through the body. The study was s…

This early-phase study tested a new drug called PRT3789 combined with the immunotherapy pembrolizumab (Keytruda) in people with advanced solid tumors that have a SMARCA4 gene mutation. The goal was to see if the combination was safe and could shrink tumors. However, the study was…

This early-stage study tested an experimental oral drug called PRT7732 in people with advanced solid tumors that have a specific genetic mutation (SMARCA4). The main goals were to check safety, find the right dose, and see if the drug could shrink tumors. The study was terminated…

This study tested a new drug combination (SON-1010 plus atezolizumab) in people with advanced solid tumors, especially platinum-resistant ovarian cancer. The goal was to see if the combination was safe and could slow tumor growth. The trial was terminated early, so results are li…

This early-phase trial tested a new drug (SAR444245) combined with an existing immunotherapy (cemiplimab) in 46 adults with advanced melanoma or squamous cell skin cancer that could not be surgically removed. The goal was to see if the combination shrank tumors. However, the stud…

This Phase 2 trial tested whether adding danvatirsen to the standard immunotherapy pembrolizumab helps people with recurrent or metastatic head and neck squamous cell carcinoma. About 69 adults with PD-L1 positive tumors were randomly assigned to receive the combination or pembro…

This early-phase trial tested the safety and dosing of a new drug called modakafusp alfa, given alone or with pembrolizumab, in adults with advanced solid tumors or melanoma. The study aimed to find the highest safe dose and check for side effects. It was terminated early, so res…

This study tested whether metformin (a diabetes drug) and doxycycline (an antibiotic) could help treat head and neck cancer when taken before surgery. The trial aimed to see if these drugs could change certain proteins in the tumor's supportive tissue. Only 7 people took part bef…

This early-phase study tested a combination of two drugs—a virus-based therapy (talimogene laherparepvec) and an antibody (panitumumab)—in 5 people with advanced skin squamous cell carcinoma that had spread or come back. The main goals were to check safety and see if tumors shran…

This phase II trial tested a combination of NBTXR3 nanoparticles (activated by radiation) and the immunotherapy drug pembrolizumab (Keytruda) in 14 people with recurrent or metastatic head and neck cancer that had limited PD-L1 expression or was resistant to PD-1 blockers. The go…

This early-phase trial tested a new treatment called HV-101 for people with advanced solid tumors that had spread or come back. The therapy uses a patient's own immune cells (TILs) taken from their tumor, grown in a lab, and then given back along with chemotherapy and IL-2. The s…

This early-phase trial tested an experimental drug called TAK-500, alone or with the immunotherapy pembrolizumab, in 61 adults with advanced solid tumors like pancreatic, liver, and lung cancer. The main goals were to check safety and see if the drug could shrink tumors. The stud…

This early-phase trial tested a personalized cancer treatment called tumor-infiltrating lymphocyte (TIL) therapy. Doctors took immune cells from each patient's own tumor, grew them in a lab, and infused them back to fight the cancer. The study enrolled only 5 adults with advanced…

This early-stage trial tested a new drug called RP-3467, alone or with olaparib, in 26 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the right dose. The study was terminated, so full results are no…

This study tested a new drug called SAR444200, alone or with other cancer treatments, in 33 adults with advanced solid tumors that had spread and were not responding to standard therapy. The main goals were to check safety and find the right dose. The trial was terminated early, …

This early-phase trial tested an experimental drug called OC-001, given alone or with the immunotherapy avelumab, in 73 people with various advanced or metastatic cancers (like lung, breast, and bladder cancer). The main goals were to check safety and how the drug moves through t…

This early-stage trial tested a combination of two drugs, APG-1387 and toripalimab, in 40 people with advanced solid tumors including colorectal, nasopharyngeal, and lung cancers. The goal was to find a safe dose and see if the combination could control the disease. However, the …

This study looked at whether a less invasive surgery (conservative surgery) could safely treat women with early-stage, low-risk cervical cancer. The goal was to see if this approach causes fewer side effects and helps recovery. The study included 137 women with stage IA2 or IB1 c…

This early-phase trial tested a radioactive drug designed to seek out and destroy cancer cells in people with advanced solid tumours that had stopped responding to other treatments. The drug targets a protein called IGF-1R found on many cancer cells. The study aimed to find a saf…

This early-phase trial tested two experimental drugs, tuvusertib and PLX038, in 10 adults with advanced solid tumors that had not responded to standard treatments. The goal was to find a safe dose and see if the combination could shrink tumors. However, the study was terminated e…

This early-phase trial tested an experimental drug called IBI3004 in people with advanced solid tumors that could not be removed by surgery. The study aimed to find a safe dose and check for side effects, but it was terminated after enrolling only 5 participants. Because it stopp…

This early-stage study tested a new drug called RO7759065, alone or with another drug (atezolizumab), in 12 people with advanced solid tumors that could not be cured. The main goals were to check safety and how the drug moves through the body. The study was stopped early, so resu…

This early-phase study tested a new drug called KZR-261 in 61 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find the right dose, and see if the drug could shrink tumors. The trial was terminated, but the…

This early-stage trial tested a new drug called M9466 combined with standard chemotherapy in people with advanced solid tumors or colorectal cancer who had no other treatment options. Only 3 people took part before the study was stopped. The main goal was to check safety and find…

This early-stage trial tested a new drug called MYTX-011 for people with advanced non-small cell lung cancer (NSCLC) that had spread or come back after standard treatments. The drug is an antibody-drug conjugate designed to deliver a powerful chemotherapy directly to cancer cells…

This study tested a peptide-based immunotherapy in 17 people with head and neck cancer who were scheduled for surgery. The goal was to see if the vaccine could boost the immune system's attack on cancer cells and to check for side effects. The trial was stopped early, but the res…

This early study tested a device that places radioactive seeds directly into skin, mouth, or soft tissue tumors. The seeds release alpha radiation to kill cancer cells from within. Only 2 people took part before the trial was stopped, so we don't have enough information to know i…

This early-phase study tested an oral drug called Debio 0123 combined with the chemotherapy carboplatin in 76 people with advanced solid tumors that had stopped responding to prior platinum-based treatments. The main goals were to find a safe dose and check for side effects. The …

This early-stage trial tested a new drug called RP-6306 combined with standard chemotherapy (FOLFIRI) in 38 adults with advanced solid tumors that had stopped responding to other treatments. The goal was to check safety, find the best dose, and see if the combo could shrink tumor…

This early-phase study tested a new oral drug (RP-6306) combined with the chemotherapy gemcitabine in 67 adults with advanced solid tumors that had stopped responding to other treatments. The main goals were to check safety, find the best dose, and see if the combination could sh…

This early-stage study tested a new drug (JS004) combined with another immunotherapy (Toripalimab) in 31 people with advanced solid tumors like liver, esophageal, stomach, cervical, or colorectal cancer. The goal was to check safety and see if the combination could help control t…

This study tested a new drug called TAK-186 in 95 adults with advanced or metastatic cancers of the head and neck, lung, or colon that could not be removed by surgery. The main goal was to check for side effects and find the best dose. The study was stopped early, so results are …

This early-phase trial tested a new drug called BLU-222, alone or with other medicines, in about 50 people with advanced solid tumors (including certain breast, ovarian, and stomach cancers). The goal was to find a safe dose and see if it shrinks tumors. However, the study was te…

This early-phase trial tested an oral drug called RP-1664 in people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to find a safe dose and check for side effects. The study was terminated early, so full results may not be availa…

This early-phase study tested a new drug called BRY805 in 13 people with advanced solid tumors who had run out of standard treatment options. The main goal was to check safety and find the right dose. The trial was terminated early, so results are limited.

This early-phase study tested whether adding the experimental drug NIS793 to standard chemotherapy (FOLFIRINOX) could help people with metastatic pancreatic cancer. Only 4 people took part before the study was stopped. The goal was to find a safe dose and see if the combination c…

This study tested a new drug called SOT101 (nanrilkefusp alfa) combined with pembrolizumab in 166 people with advanced solid tumors like lung, colon, and ovarian cancer. The goal was to see if the combo could shrink tumors. The trial was stopped early, so results are limited.

This study tested a drug called magrolimab combined with other cancer treatments for people with head and neck squamous cell carcinoma that had spread or come back. The goal was to see if the combination was safe and effective. The trial was stopped early, so results are limited.

This early-stage trial tested a new drug called FAZ053, alone or with another drug (PDR001), in 154 adults with advanced solid tumors. The goal was to check safety and find the right dose by boosting the immune system to attack cancer. The study was terminated early, so full resu…

This study tested an experimental drug called SQ3370 in 53 people with advanced solid tumors that had spread or could not be removed by surgery. The goal was to check the drug's safety and find the best dose, as well as see if it could shrink tumors. The study was terminated earl…

This study tested a personalized treatment where a patient's own immune cells were modified in a lab to recognize and attack unique markers on their cancer cells. It involved 8 people with advanced solid tumors like lung, pancreatic, or ovarian cancer that had not responded to st…

This study tested an experimental drug called ART0380 in 36 people with advanced or metastatic solid tumors, including endometrial cancer. The drug was taken by mouth and aimed to shrink tumors by blocking a protein involved in cancer cell growth. The trial was terminated early, …

This early-stage trial tested an experimental drug called NUV-868, alone or with other cancer drugs, in 82 adults with advanced solid tumors (including ovarian, pancreatic, prostate, and breast cancers). The goal was to find safe doses and check for early signs of effectiveness. …

This early-phase study tested the safety of an oral drug called LY3405105 in 54 people with advanced solid tumors. The trial was divided into two parts to find the right dose and to see if the drug could shrink tumors. However, the study was terminated early, meaning the drug did…

This early-phase trial tested a new drug, RP-3500 (camonsertib), combined with existing PARP inhibitors (niraparib or olaparib) in 156 adults with advanced solid tumors that have specific genetic markers. The goal was to find safe doses and see if the combination could shrink tum…

This early-phase study tested an experimental drug called ABBV-303, alone or with another drug (budigalimab), in adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the right dose. The study was termin…

This early-phase trial tested a new drug called INCB062079 in 25 people with advanced liver cancer and other solid tumors. The main goal was to check safety and find the best dose. The study was terminated early, so results are limited.

This study tested a combination of three drugs (azacitidine, pembrolizumab, and epacadostat) in 70 people with advanced solid tumors, including lung and colorectal cancers. The goal was to see if the combination was safe and could shrink tumors. However, the trial was terminated …

This early-stage study tested a new drug called HFB301001 in 31 adults with advanced solid tumors (like sarcoma, kidney cancer, or melanoma) that had not responded to prior treatments. The main goal was to check the drug's safety and find the best dose. The study was terminated, …

This early-stage trial tested an experimental drug called LY3127804, alone or combined with another cancer drug (ramucirumab), in 62 people with advanced solid tumors. The main goal was to find a safe dose. The study was terminated early, and researchers could not determine a max…

This study tested whether adding an immune-boosting drug (NT-I7) to a standard immunotherapy (atezolizumab) could help people with advanced skin cancers like melanoma, Merkel cell carcinoma, and squamous cell carcinoma. The trial included 31 adults whose cancer had not responded …

This study tested a combination of the experimental drug magrolimab with cetuximab and either pembrolizumab or docetaxel in people with head and neck cancer that had come back or spread. Only 4 people enrolled before the trial was stopped early. The goal was to see if the combo c…

This study tested an experimental drug called INCB057643 in 137 people with advanced cancers that had stopped responding to standard treatments. The goal was to find a safe dose and check for side effects, both when given alone and with other cancer drugs. The trial was terminate…

This early-stage study tested a new drug called ZL-1218, alone or with another cancer drug, in 34 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, side effects, and how the drug moves through the body. The …

This early-stage study tested an experimental drug called INCB099318 in people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check the drug's safety and how the body processes it. The study was terminated early, so results are…

This early-stage study tested a new drug called ACTM-838 in 10 people with advanced solid tumors that no longer responded to standard treatments. The main goals were to check safety and find the right dose. The study was stopped early, so results are limited.

This phase 2 trial tested the drug futibatinib in 115 people with advanced solid tumors or blood cancers that have specific FGFR gene changes. The goal was to see if the drug could shrink tumors or cause remission. The study was terminated early, so final results are not yet clea…

This phase 3 study tested whether adding the experimental drug Xevinapant to standard chemoradiotherapy could improve outcomes for people with locally advanced head and neck cancer. The trial planned to enroll 730 participants but was terminated early. The main goal was to see if…

This study looked at whether adding the immunotherapy drug nivolumab to standard chemotherapy could help people with nasopharyngeal cancer that has returned or spread. The trial was planned for many participants but was stopped early, so only 15 people took part. Because of the e…

This phase 2 trial tested the drug tovorafenib (DAY101) in 23 people aged 12 and older with recurrent or progressive solid tumors that have specific genetic changes in the MAPK pathway. The goal was to see how many patients' tumors shrank or disappeared. The study was terminated …

This early-stage trial tested two drug combinations—TNO155 plus spartalizumab or ribociclib—in 122 adults with advanced solid tumors like lung, head and neck, and colorectal cancers. The goal was to check safety and see if the drugs could slow cancer growth. The study was termina…

This early-phase study tested the drug INCB086550 in 3 Japanese patients with advanced solid tumors that had stopped responding to other treatments. The main goal was to check safety and find the right dose. The study was terminated early, so we have limited information on how we…

This early-phase trial tested an experimental oral drug called NKT3447 in 23 adults with advanced or metastatic solid tumors that had stopped responding to standard treatments. The goal was to check safety, find the right dose, and see if the drug could shrink tumors. The study w…

This study tested a new drug called LB101 in 25 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to check safety and see if the drug shrank tumors. The study was terminated early, so results are limited.

This phase 2 trial tested two drugs—ulixertinib and hydroxychloroquine—in 47 people with advanced gastrointestinal cancers that have certain genetic mutations (MAPK pathway). The goal was to see if the combination could shrink tumors. However, the study was terminated early, so t…

This phase 2 trial tested a new drug called SAR444245 combined with either pembrolizumab or cetuximab in 59 adults with head and neck cancer that had spread or come back. The goal was to see if the combinations could shrink tumors. However, the study was terminated early, so we d…

This early study tested an experimental oral drug called IK-595 in people with advanced solid tumors that have specific RAS or RAF gene mutations. The goal was to check safety, dosing, and early signs of tumor shrinkage. The study was terminated before completion, so full results…

This early-phase trial tested a new drug called BGB-30813, either alone or combined with the immunotherapy tislelizumab, in 44 people with advanced solid tumors that had not responded to standard treatments. The main goals were to check safety, find the right dose, and see if the…

This early-phase trial tested a drug called RiMO-401, injected directly into tumors and followed by radiation, in people with advanced cancers that had not responded to standard treatments. Only 5 patients were enrolled before the study was terminated. The main goal was to find a…

This early-stage trial tested a new drug, PF-07820435, alone or with another immunotherapy (sasanlimab) in 9 people with advanced solid tumors like lung, skin, or kidney cancer. The main goals were to check safety and find the right dose. The study was terminated early, so result…

This early-phase study tested an experimental drug called KD033 (SAR445710) in 45 adults with advanced or metastatic solid tumors. The main goal was to check safety and find the right dose, while also looking for any anti-cancer effects. The trial was terminated, so final results…

This early-phase study tested an experimental drug called BMS-986258, alone or combined with the immunotherapy nivolumab (Opdivo), in 92 people with advanced solid tumors like lung, kidney, or breast cancer. The main goal was to check safety and find the right dose. However, the …

This early-phase trial tested a new drug called LB4330 in people with advanced solid tumors that had stopped responding to standard treatments. LB4330 is designed to help the immune system attack cancer cells. The study aimed to find a safe dose and check for side effects, but it…

This early-stage trial tested an experimental drug called SAR441000, injected directly into tumors, either alone or with another drug (cemiplimab) given through a vein. The study aimed to find a safe dose and see if the combination could shrink tumors in people with advanced soli…

This early-phase trial tested an experimental drug called INCA00186, alone or with other immunotherapy drugs, in people with advanced solid tumors such as head and neck or gastrointestinal cancers. The study aimed to find safe doses and check for early signs of effectiveness. It …

This study tested whether a special imaging technique called narrow band imaging (NBI) can help surgeons find early cancer spots in the mouth that are not visible under normal light. The trial involved 23 people with oral cancer who were already scheduled for surgery. Doctors com…

This study tested a dye called tozuleristide that makes oral cancer cells glow under special light during surgery. The goal was to help surgeons see and remove all cancer while sparing healthy tissue. The trial included 8 adults with oral cavity cancer or high-grade dysplasia. Th…

This study tested whether a device called the Sklip System, which uses artificial intelligence, could help people at home decide if a mole might be skin cancer. Only one person took part before the study was stopped early. The goal was to see if the AI could match or beat standar…

This small pilot study tested whether applying acupressure to the ear could help improve appetite and prevent weight loss in people with advanced stomach, esophagus, or pancreatic cancer. The approach uses small adhesive pellets placed on specific ear spots to stimulate the nervo…

This early-phase study aimed to see if adding the drug xevinapant to standard chemoradiotherapy is safe for people with advanced head and neck cancer that cannot be removed by surgery. The study planned to enroll 18 participants but was terminated early. The main focus was on sid…

This study aimed to find out how often liver fibrosis and cirrhosis occur in people with head and neck cancer, since tobacco and alcohol are risk factors for both. Researchers planned to check liver health using exams and imaging. However, the study was stopped early after only 2…

This study aimed to help low-income pregnant women stop smoking and make their homes smoke-free. Smoking during pregnancy raises the risk of cancer and can lead to low birth weight and other health problems for the baby. The program offered support and referrals to services durin…

This pilot study tested whether a new PET imaging tracer called [18F]F-AraG could track immune T cells inside tumors of patients with advanced solid cancers who were receiving immunotherapy. Nine patients were enrolled to have PET scans and tumor biopsies before and after treatme…

This study aimed to find out if patients with metastatic esophageal cancer who were not getting worse after 6 weeks of chemotherapy should continue treatment or stop. It included 15 adults whose cancer had spread and was no longer responding to initial chemo. The study was termin…

This study aimed to see if regular ultrasound scans of lymph nodes could detect the spread of high-risk skin cancer on the head or neck earlier than usual. It planned to enroll patients with aggressive tumors or weakened immune systems. However, the study was terminated after onl…

This study aimed to find the best way to follow up with patients after they finish curative treatment for head and neck cancer. Researchers compared a personalized follow-up schedule, tailored to each patient's needs, with the usual one-size-fits-all approach. The goal was to see…

This study used PET scans to track where a new antibody drug (S095012) goes in the body and in tumors of people with advanced solid cancers. Only 3 participants were enrolled before the study was stopped early. The goal was to understand how the drug spreads and targets tumors, n…

This study aimed to see if a culturally tailored educational video could help African American, Korean, and Chinese adults learn about lung cancer and screening. Researchers planned focus groups and interviews with 11 participants to understand barriers. The trial was terminated …

This early-stage study aimed to see how the experimental drug ceralasertib affects the way the body processes three other drugs (Drug X, Y, and Z) in people with advanced solid tumours. Only one person was enrolled before the study was terminated, so no useful information was gat…

This early-phase study aimed to use PET imaging to track how a new drug (BI 754111) spreads in the body and reaches tumors in people with advanced non-small cell lung cancer or head and neck cancer. Only 8 participants were planned, and the study was terminated early. The main go…

This study tested a new planning method to protect areas where dental implants could later be placed in patients receiving radiation for head and neck cancer. Researchers used virtual implant markers on CT scans to adjust radiation doses, aiming to keep implant sites safe without…

This study aimed to find genetic changes in lung tissue and blood that could predict how squamous cell lung cancer progresses. Researchers planned to collect samples from 200 patients undergoing lung procedures, but the study was stopped early with only 22 participants. No treatm…

This study looked at how adults with advanced or metastatic solid tumors absorb, break down, and remove the drug subasumstat. Only 3 people took part, and the study was stopped early. The goal was to measure the drug in urine and stool, not to test if it works as a treatment.

This study aimed to gather information from about 500 people with penile cancer to better understand the disease, its risk factors, treatments, and outcomes. Researchers did not provide any new treatment or intervention. The study was stopped early, but the data collected may hel…

This early-phase trial aimed to see how a new version of the chemotherapy drug paclitaxel, called FID-007, affects immune cells in head and neck cancer tumors. Researchers planned to study tumor samples before and after treatment in people scheduled for surgery. However, the stud…